4779-37-7

Usage

Uses

Used in Organic Synthesis:
2-bromo-1-[4-(phenylsulfonyl)phenyl]ethanone is used as a reagent in organic synthesis for its ability to facilitate the formation of new chemical bonds and structures. Its unique properties make it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-bromo-1-[4-(phenylsulfonyl)phenyl]ethanone is utilized as a starting material or intermediate in the development of new drug molecules. Its potential antibacterial and anti-inflammatory properties make it a promising candidate for the treatment of various diseases and conditions.
Used in Materials Science:
2-bromo-1-[4-(phenylsulfonyl)phenyl]ethanone is studied for its potential application in the field of materials science, particularly in the development of organic semiconductor materials. Its unique properties may contribute to the advancement of electronic devices and other technologies that rely on organic semiconductors.
Used in Antibacterial Applications:
2-bromo-1-[4-(phenylsulfonyl)phenyl]ethanone is used as an antibacterial agent due to its ability to inhibit the growth of certain bacteria. This property makes it a potential candidate for the development of new antimicrobial drugs and treatments.
Used in Anti-inflammatory Applications:
The anti-inflammatory properties of 2-bromo-1-[4-(phenylsulfonyl)phenyl]ethanone make it a potential candidate for the development of new anti-inflammatory drugs. These drugs could be used to treat various inflammatory conditions and diseases.

Upstream product

• 65085-83-8 4'-(phenylsulfonyl)acetophenone 
• 108-98-5 thiophenol 
• 1194-02-1 4-fluorobenzonitrile 
• 51238-46-1 4-(phenylthio)benzonitrile 
• 28525-13-5 4-(phenylsulfonyl)benzonitrile 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 873-55-2 sodium benzenesulfonate 

Downstream Products

• 1621085-13-9 2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)phenyl)ethanone 
• 1621085-17-3 2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)propyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)phenyl)ethanone 
• 1621085-25-3 2-(4-(((1-(1-(2-oxo-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)phenyl)ethanone 
• 1426938-41-1 C₂₄H₂₇NO₇S 

Relevant academic research and scientific papers

Microwaves assisted synthesis of antitumor agents of novel azoles, azines, and azoloazines pendant to phenyl sulfone moiety and molecular docking for VEGFR-2 kinase

The present research article contains two valuable starting phenylsulfone-enaminones which were synthesized in short reaction time with excellent yield under microwaves irradiation. These two enaminones were reacted with both nucleophiles and electrophiles to afford novel heterocycles bearing phenylsulfone moiety. The structure of all prepared phenylsulfone derivatives as well as their mechanistic pathways were studied based on their spectral data. Moreover, seventeen phenylsulfone derivatives were screened in vitro for their anticancer activity against HepG-2 and HCT-116 cell lines. Compounds 4 and 7a were equipotent to doxorubicin against HepG-2 cell line. Moreover, diphenyl sulfone derivative 7a was 3-fold more potent than doxorubicin against human colon cancer cell line with IC50 = 3.13 and 9.4 μg/mL, respectively. Remarkably, compound 7b was 2-fold more active than doxorubicin against the two tested cell lines. A docking study of title compounds into VEGFR-2 kinase was also conducted.

Synthesis and antimicrobial evaluation of novel pyrazolopyrimidines incorporated with mono- And diphenylsulfonyl groups

A novel series of pyrazolo[1,5-a]pyrimidine ring systems containing phenylsulfonyl moiety have been synthesized via the reaction of 2-(phenylsulfonyl)-1-(4-(phenylsulfonyl) phenyl)ethan-1-one, 2-benzenesulfonyl-1-(4-benzenesulfonyl-phenyl)-3-dimethylamino-propenone and 3-(dimethylamino)-1-(4-(phenylsulfonyl)phenyl)prop-2-en-1-one each with various substituted aminoazopyrazole derivatives in one pot reaction strategy. The proposed structure as well as the mechanism of their reactions were discussed and proved with all possible spectral data. The results of antimicrobial activities of the new sulfone derivatives revealed that several derivatives showed activity exceeding the activity of reference drug. Contrary to expectations, we found that derivatives containing one sulfone group are more effective against all bacteria and fungi used than those contain two sulfone groups.

Catalytic dehydrogenative dual functionalization of ethers: Dealkylation-oxidation-bromination accompanied by C-O bond cleavage: Via aerobic oxidation of bromide

Catalytic dehydrogenative dual functionalization (DDF) of ethers via oxidation, dealkylation, and α-bromination by the aerobic oxidation of bromide was developed to obtain the corresponding α-bromo ketones in high yields. In particular, the reaction of substituted tetrahydrofurans as cyclic ethers provided 3,3-dibromo tetrahydrofuran-2-ols in high yields selectively through the double α-bromination.

BIARYL INHIBITORS OF THE SODIUM CHANNEL

The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns biaryl derivatives (e.g., compounds according to any of Formulas (I)-(XII) or Compounds (l)-(372) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors

Based on the symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed. The synthesis of 36 new non-dimeric NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. Among them compound 5a showed picomolar range activity along with an excellent selectivity index (SI > 90,000).